Comment on "Postmarketing adverse events of tamoxifen in male and female patients with breast cancer"
Int J Cancer
.
2025 Feb 15;156(4):889-890.
doi: 10.1002/ijc.35243.
Epub 2024 Oct 29.
Authors
Yoshihiro Noguchi
1
,
Yoko Ino
2
,
Ryo Kobayashi
3
,
Tomoaki Yoshimura
1
Affiliations
1
Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.
2
Laboratory of Pharmaceutical Health Care and Promotion, Gifu Pharmaceutical University, Gifu, Japan.
3
Laboratory of Advanced Medical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.
PMID:
39472289
DOI:
10.1002/ijc.35243
No abstract available
Publication types
Letter
Grants and funding
22K12890/JSPS KAKENHI
24K09916/JSPS KAKENHI